CD Biosynsis offers end-to-end CHO (Chinese Hamster Ovary) Cells Genome Editing and Metabolic Engineering Solutions, providing a complete platform for developing high-performance production strains in this premier mammalian host. CHO cells are the industry workhorse, distinguished by their mammalian protein processing, complex post-translational modifications (PTMs), and suitability for clinical biomanufacturing. Our solutions integrate cutting-edge CRISPR-based genome editing tools (KO, KI, BE, and CRISPRi) with rational design methodologies (metabolic modeling and high-throughput screening). We handle the entire engineering process, from initial target identification and pathway optimization to final strain stability validation, guaranteeing the rapid and successful development of CHO cell lines for superior bioprocessing productivity and product quality.
Get a QuoteThe core challenge in engineering CHO cells is managing the trade-off between cell viability, specific productivity ($\text{Q}_\text{p}$), and product quality (CQAs). Our platform ensures that modifications are strategically optimized to resolve metabolic bottlenecks (lactate/ammonia) and enhance cellular fitness (anti-apoptosis). By coupling precision genome editing with systematic analysis, we enable the rational development of strains that can stably produce complex molecules at high titers, managing the entire bioproduction pipeline from gene to clinic.
Comprehensive services covering all modifications: stable Knock-ins (KI) into safe harbor loci and multi-allelic deletions (KO).
Multiplexed CRISPR strategies for simultaneous disruption of multiple genes (e.g., proteases, pro-apoptosis regulators) via NHEJ/HDR.
Tools for fine-tuning: BE for single-nucleotide precision (promoters/PTMs) and CRISPRi for reversible gene knockdown (metabolic enzymes).
Systematic optimization focusing on reducing toxic byproducts (lactate/ammonia) and enhancing central carbon metabolism and anti-apoptosis pathways.
Glycoprofile Engineering
Targeted editing of the glycosylation machinery (KO/KI/BE) to achieve desired N-glycan homogeneity, crucial for therapeutic efficacy and safety.
Cellular Fitness Enhancement
Modification of ER/Golgi chaperones and stress response genes to improve protein folding capacity and extend cell viability in the bioreactor.
Computational prediction (CBM) and experimental verification (Fluxomics, Glycan Analysis) to guide rational design and fed-batch strategy.
High-speed, large-scale production and purification of recombinant proteins, ensuring correct folding, PTMs, and regulatory compliance.
Rapid, automated high-throughput screening (HTS) and iterative optimization for isolating high-producer, stable monoclonal cell lines (MCB).
A seamless, project-based pathway from rational design to industrial strain readiness.
1. Rational Target Identification
2. Precision Genomic Modification
3. High-Throughput Phenotyping
4. Clone Verification & Delivery
Utilize metabolic modeling (Assay & Modeling) to analyze the CHO cell metabolism and identify limiting factors (lactate shunt, apoptosis).
Design a comprehensive strategy including KO, KI, and regulatory tuning targets for maximum product yield and quality (Glycoprofile Engineering).
Define HTS assay metrics for specific productivity ($\text{Q}_\text{p}$) and CQAs.
Apply optimized CRISPR-based tools (Genome Editing) to construct rationally designed strain variants or libraries.
Perform multi-gene knockouts (Multi-Gene Knockout) and stable chromosomal knock-ins of expression cassettes.
Ensure all edits are verified in the bulk population.
Select the lead clone based on titer, stability, and CQA analysis.
Genomic verification and stability testing of the final monoclonal cell line.
Delivery of the verified CHO master cell bank (MCB) and all associated data.
Integrated Bioprocess Control
Solutions integrate tools that target core bioprocess limitations: apoptosis (longevity) and byproduct accumulation (lactate/ammonia), maximizing final product titer.
Precision Glycoengineering
Utilizes CRISPR/Base Editing alongside Glycan Analysis to tailor the N-glycan profile for optimal therapeutic efficacy and reduced immunogenicity.
Stable Monoclonal Lines
Focus on CRISPR/HDR integration into safe harbors and automated single-cell cloning ensures genetic stability, true clonality, and regulatory compliance (MCB).
Full Mammalian Toolset
Single-platform access to all necessary tools (Modeling, CRISPR, HTS, PTM Analysis) required for complex, high-titer therapeutic protein development.
1. What makes CHO Cells the best host for biopharma solutions?
CHO cells are mammalian, providing the essential machinery for correct protein folding, complex PTMs, and human-compatible glycosylation, combined with decades of proven regulatory acceptance for clinical use.
2. How do you achieve stable expression for industrial manufacturing?
We use CRISPR/HDR to integrate the gene cassette into defined genomic safe harbor loci. This eliminates the risk of gene silencing and position effects associated with random integration, ensuring long-term stable production.
3. How is toxic byproduct accumulation managed?
We use Assay & Modeling to identify the metabolic bottlenecks (e.g., LDHA/GS). Then, we apply precision editing (BE/CRISPRi) to tune the activity of these enzymes, minimizing lactate and ammonia accumulation while preserving cell viability.
4. What is the role of HTS and Single Cell Cloning?
HTS rapidly screens thousands of engineered clones for high specific productivity ($\text{Q}_\text{p}$) and desired CQAs. Automated single-cell cloning then guarantees that the selected high-producer is a true monoclonal line, required for regulatory approval.
5. Why is Multi-Gene Knockout needed in CHO cells?
Multi-gene knockout is needed to systematically remove complex traits like multiple native host proteases or all alleles of key glycosylation genes (e.g., FUT8) to ensure complete loss of undesirable function.
6. How do you ensure the final product quality (CQA)?
CQA control is achieved through Glycoprofile Engineering and targeted editing of folding pathways. We use Glycan Analysis in the Assay phase to confirm that the editing strategy yields the optimal human-like N-glycan structure.
7. What input is required for a complete solutions project?
We require the specific therapeutic protein sequence (e.g., mAb heavy/light chain), the CHO host cell line, and the primary optimization goals (e.g., increase titer, achieve afucosylation, improve viability).
8. What is included in the final delivery package?
The final delivery includes the optimized CHO master cell bank (MCB), a full report detailing all genomic modifications, stability data, and fed-batch performance metrics (titer, viability, and CQA analysis).
CRISPR-Cas9 technology represents a transformative advancement in gene editing techniques. The main function of the system is to precisely cut DNA sequences by combining guide RNA (gRNA) with the Cas9 protein. This technology became a mainstream genome editing tool quickly after its 2012 introduction because of its efficient, simple and low-cost nature.
The CRISPR gene editing system with its Cas9 version stands as a vital instrument for current biological research. CRISPR technology enables gene knockout (KO) through permanent gene expression blockage achieved by sequence disruption. Various scientific domains including disease modeling and drug screening employ this technology to study gene functions. CRISPR KO technology demonstrates high efficiency and precision but requires confirmation and verification post-implementation because unsatisfactory editing may produce off-target effects or incomplete gene knockouts which impact experimental result reliability. For precise and efficient Gene Editing Services - CD Biosynsis, Biosynsis offers comprehensive solutions tailored to your research needs.
The CRISPR-Cas9 knockout cell line was developed using CRISPR/Cas9 gene editing to allow scientists to remove genes accurately for research on gene function and disease models and pharmaceutical discovery. Genetic research considers this technology essential due to its high efficiency together with simple operation and broad usability.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
|
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.